Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia to Merge Four Software Divisions into Single Unit

NEW YORK, Feb 26 – Pharmacopeia of Princeton, NJ, said Monday it would combine its four life science software units into a single entity, effective June 1.

“We’ve been acquiring different software businesses all related to drug discovery and chemical development, so we’re going to continue doing what we do, which is design and sell software to help our customers discover drugs and develop chemicals, but now we’ll just do it under one name since all the products are basically related,” Sue Rodney, manager of investor relations at Pharmacopeia, told GenomeWeb.

Rodney did not comment on whether merging the business units would result in layoffs.

The new software business will incorporate Molecular Simulations, Genetics Computer Group, Oxford Molecular Group, and Synopsys Scientific Systems. The software unit, for which a name has been chosen but not disclosed, will be based in San Diego and Cambridge, UK.  

Michael Stapleton, who was recently promoted to chief operating officer of Pharmacopeia’s software business, will head the new organization.    

An official announcement of the new unit will take place at the American Chemical Society Meeting in San Diego April 1-5.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.